Target intelligence / Profile preview

Chromobox protein homolog 3 (CBX3)

Target
CBX3
Molecular classification
Chromatin-associated protein, Epigenetic regulator, Reader of histone methylation, Heterochromatin protein 1 family (HP1), Nonhistone chromosomal protein
01

Overview

**Chromobox protein homolog 3 (CBX3 or HP1γ)** is a nonhistone chromosomal protein and key component of the heterochromatin protein 1 (HP1) family[1][2]. It binds specifically to histone H3 methylated at lysine 9 (H3K9me2/3) via its chromodomain, participating in the establishment and spread of heterochromatin regions, which leads to transcriptional silencing of genes[1][2][3]. CBX3 influences gene expression, chromatin organization, cell cycle progression, apoptosis, and is implicated in cancer progression. It interacts with various other nuclear proteins (e.g., lamin B receptor, PIM1, Ki-67, CBX5, CBX1) and can act as a scaffold for the recruitment of enzymatic modifiers of chromatin structure[1]. CBX3 is considered a promising but challenging therapeutic target in oncology and epigenetic drug development due to its multifaceted role in chromatin biology[2][3].

Other names
CBX3HP1γHeterochromatin protein 1 gammaHP1-gamma
02

Mechanism of action

Agents targeting CBX3 seek to modulate heterochromatin formation and epigenetic gene silencing, especially by interfering with its binding to methylated histones (e.g., H3K9me2/3) or disrupting protein-protein interactions fundamental to the formation of transcriptionally repressive chromatin[2][3].

03

Biological functions

Heterochromatin formationGene silencingChromatin remodelingRegulation of transcriptionCell cycle controlEmbryonic developmentCell proliferationApoptosis
04

Disease associations

Cancer (including prostate carcinoma, glioma, hepatocellular carcinoma, colon adenocarcinoma, lymphoma)Other (abnormalities in cell proliferation and gene silencing)
05

Safety considerations

Given its central role in global chromatin regulation and gene silencing, targeting CBX3 could broadly affect cell viability, differentiation, and genome stability, raising the risk of off-target effects and undesired impacts on normal tissues.Potential adverse effects may include disruption of essential gene silencing, increased genomic instability, or interference with normal cell cycle progression[3].
06

Interacting drugs

No approved drugs directly and selectively targeting CBX3/HP1γ are currently well established.

1 more in the full profile.

07

Biomarkers

CBX3/HP1γ expression is used as a biomarker for aggressive behavior and prognosis in various cancers; overexpression is frequently associated with tumor progression[2].

Beyond the preview

Go deeper on Chromobox protein homolog 3 (CBX3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chromobox protein homolog 3 (CBX3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call